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The interaction between HIV infection and psychiatric 
illness is complex, with many authors suggesting that 
psychiatric disorders in HIV-positive individuals are fre-
quently under-recognised and under-treated.2,3 It is well 
established that there is an increase in the prevalence 
of a number of psychiatric disorders in HIV-infected in-
dividuals, internationally4,5  and in South Africa.6,7 There 
may also be changes in the clinical picture in patients 
with psychiatric disorders after HIV infection8 and an in-
teractive effect between HIV infection and vulnerability 
to psychiatric illness.9
In patients on ART who may require psychotropic medi-
cation important considerations include possible side-
effects of existing antiretroviral medications, as well as 
potential interactions between ART and psychotropics. 
Psychosis, mania, agitation and suicidal ideation have 
all been associated with ART. The antiretroviral agents 
most commonly implicated include abacavir, efavirenz 
and nevirapine.10 Although in most cases it would ap-
pear that the psychiatric adverse effects occurred short-
ly after initiation of the antiretroviral agent, cases oc-
curring over a year after commencement have also been 
reported. 
Drug interactions between ART and psychotropic medi-
cation, as well as with other medications the patient 
may be receiving, is another area that must be ap-
proached with some caution. A number of psychotropic 
agents that are potent enzyme inducers are contra- 
indicated for use with almost all antiretroviral agents 
as they can seriously compromise antiretroviral therapy; 
these include carbamazepine, phenytoin, primidone and 
St John’s wort. Caution is also advised when using cer-
tain selective serotonin re-uptake inhibitors (SSRIs) and 
benzodiazepines (see below). 
With regard to the antiretrovirals, a wide range of inter-
actions with psychotropic agents have been described, 
and careful observation in the first weeks to months 
after any change of these medications is required. All 
the protease inhibitors, as well as the non-nucleoside 
reverse transcriptase inhibitors, are metabolised by the 
cytochrome P450 system and may therefore possess en-
zyme-inducing or inhibiting properties. In the South Af-
rican setting, the commonly used agents that require the 
most caution are efaverinz, which may induce or inhibit 
CYP3A4, and nevirapine, which may induce CYP3A4. 
Many other antiretrovirals have been reported as inter-
acting with psychotropics, and a more comprehensive 
list of interactions can be obtained at the HIV InSite Da-
tabase of Antiretroviral Drug Interactions (http://www.
hivinsite.com/11).10
It is also critical to take into account a wide range of 
psychosocial factors that may adversely affect the indi-
vidual patient’s willingness and capacity to take medi-
cation correctly and for the required duration.
n  Many HIV-positive patients may already be on com-
plex drug regimens.
n  Patients are often going through a complex process 
of adjustment to and acceptance of a lifelong diag-
nosis of HIV/AIDS with associated stigmatisation.
n  Many of these patients will be suffering from some 
degree of cognitive impairment.
n  In many psychiatric disorders, particularly those as-
sociated with psychosis, insight may be lacking or 
may fluctuate.
When these issues are considered in their entirety, it 
becomes clear that the importance of selecting the 
simplest possible regimens, the provision of regular psy-
cho-education and counselling, and  the recruitment of 
family members or others as treatment partners for all 
the medications the patient may be receiving cannot be 
emphasised too strongly.
While this review is based as far as possible on the ex-
isting evidence base for psychotropic medication use in 
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HIV/AIDS, it is important to note that empirical evidence 
is limited in many instances. Data often come from stud-
ies outside sub-Saharan Africa, and in turn the applica-
bility of such evidence to South African populations may 
require interrogation. 
anXieTY DisOrDers
The vast majority of the existing literature on the treat-
ment of these disorders in HIV-positive patients de-
scribes the use of psychotherapeutic approaches rather 
than medication. As an initial approach, this is perhaps 
appropriate in general populations.
Benzodiazepines have been shown to provide rapid symp-
tomatic relief from acute anxiety states, but they should 
be used with caution in post-traumatic stress disorder 
(PTSD) and panic disorders, and they have severe limi-
tations in terms of their capacity to produce tolerance 
and dependence.12 There is no reason to believe that the 
situation differs in HIV. Further caution must be applied 
with the use of alprazolam, midazolam and triazolam, 
which are dependent on CYP3A4 for metabolism, so that 
inhibitors of this enzyme system may increase the half-
life of these drugs, possibly causing over-sedation and 
respiratory depression. Additionally, CYP3A4 inducers 
may lower serum levels and reduce the effect of these 
drugs.13 Perhaps safer choices are benzodiazepines such 
as oxazepam, lorazepam, and temazepam, which are 
metabolised by glucuronidation.3 However, a cautious 
approach is required in all cases, with careful titration of 
initial doses and observation for accumulation.
There is some evidence in support of buspirone as an 
anxiolytic in HIV-positive individuals, as reported in two 
small studies.14,15 However there are also reports of dys-
kinesias, myoclonus, psychosis and mania in HIV-posi-
tive patients.
Lastly, and perhaps of most clinical relevance, it should 
be noted that the SSRIs are widely recommended as 
first-line treatment for a variety of anxiety disorders, 
including PTSD, generalised anxiety disorder (GAD), 
panic disorder and obsessive-compulsive disorder in the 
general population.10 There is little evidence to suggest 
this is not the case in HIV-infected individuals, and the 
use of these drugs is discussed below. In using the SSRIs 
to treat anxiety disorders it is useful to initiate medi-
cation at smaller doses than is usual for the treatment 
of depression, and in some cases the brief use of small 
doses of benzodiazepines during the initial period may 
be helpful.
Alternative hypnotics, such as zopiclone and zolpi-
dem, should be used with caution as interactions with 
CYP3A4 have been reported. Beta-blockers are some-
times used in the treatment of GAD, but in the context 
of HIV, consideration must be given to the possibility 
of respiratory disorders and peripheral neuropathies, in 
which case these agents are best avoided.
DepressiOn
Depressive disorders and their treatment in HIV-posi-
tive populations have received far more attention than 
other psychiatric disorders. A particular area of concern 
has been raised by studies indicating poor adherence to 
ART regimens16  and increased morbidity17  in HIV-posi-
tive patients with untreated depression. Despite this, a 
systematic review and meta-analysis of controlled trials 
to examine efficacy of antidepressant treatment among 
HIV-positive depressed individuals18 identified only sev-
en studies, almost all of which involved white males in 
First-World populations. Of these, only three (involving 
fluoxetine, paroxetine and imipramine) reported signifi-
cant effects.
Looking more broadly at the literature on tricyclic anti-
depressants (TCAs), there is evidence to suggest that re-
sponse rates are similar to those in HIV-negative popu-
lations19  and that these agents are as effective as SSRIs 
in depressed HIV-positive patients.20 It would therefore 
seem that TCAs are an appropriate choice in this context. 
It is, however, important to consider a number of issues 
relating to the side-effects of these drugs, particularly 
anticholinergic effects (which may lead to dry mucous 
membranes and an increased vulnerability to mucocu-
taneous candidiasis), alpha-adrenergic blockade (which 
can result in problematic postural hypotension, particu-
larly in patients with neuropathies and other systemic 
illnesses), and prolongation of the QTc interval. Other is-
sues such as the potential for sedation and weight gain 
may be problematic or beneficial, depending on the par-
ticular circumstances.
With regard to the SSRIs, although the best evidence for 
efficacy to date favours fluoxetine and paroxetine, these 
agents are potentially problematic in conjunction with 
ART (in particular nevirapine and ritonavir) as both are 
metabolised by CYP2D6, while fluoxetine also inhibits 
CYP3A4; there is therefore an increased risk of serotonin 
syndrome, as well as of changes in levels of antiretro-
virals. Although the quality of evidence for the efficacy 
of both citalopram and sertraline in HIV-positive popu-
lations is less compelling, some evidence does exist21,22 
and there is little to suggest interaction with CYP2D6 
or CYP3A4. Possible side-effects that may be of con-
cern with this class of drugs include gastro-intestinal 
disturbances and increased anxiety. These can, however, 
be mitigated by initiating therapy with low doses and 
slowly increasing to therapeutic levels. 
There is weak evidence to support the efficacy of new-
er-generation antidepressants in treating depression in 
HIV-infected patients.23 Mirtazapine has minimal ef-
fect on CYP2D6 or CYP3A410 and has proved a popu-
lar choice because of its relatively sedating effects and 
tendency to improve appetite and promote weight gain.3 
There is currently little evidence on the use of venlafax-
ine and duoloxetine in depressed HIV-positive patients, 
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and metabolism by CYP2D6 and inhibition of this system 
would argue against their use as a first-line treatment. 
Bupropion has been studied in one open trial for depres-
sion in HIV-positive patients and was found to be ef-
fective,22 but there are concerns that efavirenz, ritonavir 
and nelfinavir may increase levels by inhibiting bupro-
pion hydroxylation.3
A number of alternative agents for the treatment of 
depression have been studied quite extensively in HIV. 
Concerns have been expressed about potential interac-
tions between St John’s wort and various antiretrovi-
rals,24 so this is best avoided. Testosterone may be of use 
in men with hypogonadism, which may occur as a result 
of HIV infection,25 but is not broadly effective as an anti-
depressant. With regard to psychostimulants, their po-
tential side-effect profile, which includes psychosis, ma-
nia, weight loss, anxiety, insomnia and cognitive deficits, 
would mitigate against their use as first-choice agents.  
Finally, the use of electroconvulsive therapy should not 
be overlooked in cases of treatment resistance or where 
medication has not been tolerated. Although not well 
studied in HIV, there are reports of its beneficial use26,27 
and it should not be refused simply on the basis of HIV 
status.   
bipOlar DisOrDer anD Mania
Manic episodes, either as part of bipolar disorder or as a 
secondary complication of HIV infection,5,28 are well de-
scribed in HIV. In a first manic episode it may be prefer-
able to avoid the immediate use of a mood stabiliser in 
favour of an antipsychotic (see ‘Psychosis’, below), with 
short-term use of benzodiazepines (see ‘Anxiety Disorders’, 
above) if necessary. In established bipolar disorder, recur-
rent or relapsing secondary mania, or where this initial 
approach has proven inadequate, the use of mood stabi-
lisers is indicated. In bipolar mania the preferred first-line 
mood stabilisers are lithium and sodium valproate, with 
carbamazepine as a second choice.10 As mentioned earlier, 
however, the potent enzyme induction attributed to car-
bamazepine makes it a poor choice in HIV.
There are mixed reports on the use of lithium in HIV-
positive patients. Concerns have been expressed regard-
ing possible increased sensitivity to side-effects29 and 
worsening of cognitive impairment;30 however, a recent 
study31 demonstrated quite the opposite, with improve-
ments in HIV-associated neurocognitive impairment on 
lithium. This may be related to its capacity, together 
with sodium valproate, for the inhibition of glycogen 
synthase kinase 3 beta (GSK-3 beta), a survival-regu-
lating enzyme.32,33 Lithium is excreted unchanged in the 
urine, so interactions with ART are unlikely. Its narrow 
therapeutic index, however, is of some concern, particu-
larly when diarrhoea is likely, and extreme caution is re-
quired with medications that may reduce the glomerular 
filtration rate. It can therefore be concluded that lithium 
may be a reasonable choice, provided that it is well tol-
erated on initiation and that excellent compliance can 
be guaranteed.
Valproate (available as sodium valproate or valproic 
acid) is generally considered to be better tolerated 
than lithium and safer with regard to therapeutic in-
dex, but neutropenia, hepatic failure and the potential 
for teratogenesis in women of child-bearing age remain 
a concern.10 Its potential to inhibit CYP3A4 may result 
in interactions with some antiretrovirals, and caution is 
advised when using it in combination with nevirapine 
and efaverinz. It has also been shown to inhibit GSK-3 
beta.33 Early reports raised some concerns that it may 
increase viral loads by stimulating replication.34 More re-
cently it was suggested that this effect, in combination 
with ART, may lead to the possibility of cure by depleting 
latent viral stores,35 but unfortunately this has not been 
substantiated.36 Whether sodium valproate may lead to 
cognitive decline in HIV-positive individuals or not is not 
entirely resolved, however, with some studies showing 
no decline37,38 but one study suggesting problems with 
longer-term use at higher doses.39 This concern is sup-
ported by a fairly extensive literature pointing to adverse 
neurocognitive effects of valproate in individuals with 
cognitive impairment, although it should be noted that 
valproate is not unique in this effect either (e.g. Gualtieri 
and Johnson40). While valproate is therefore probably a 
reasonable choice of mood stabiliser in this setting, it 
would seem prudent to exercise caution with higher 
doses and to monitor cognitive function carefully, short-
ly after initiation as well as in the longer term.
psYcHOsis
The older ‘classic’ antipsychotics, haloperidol in particu-
lar, have been shown to be safe and effective in studies 
of HIV-infected patients with schizophrenia8 as well as 
those with HIV-associated psychotic disorder.41,42 How-
ever, these patient groups have increased susceptibility 
to extrapyramidal side-effects (EPSE) and possibly to 
tardive dyskinesia (TD) and neuroleptic malignant syn-
drome.10 Although chlorpromazine may be less likely to 
produce EPSE and is helpful in restless patients when 
benzodiazepines are not well tolerated, this is similarly 
limited to a lower dosage range. Further problems in-
clude the well-established side-effects of neutropenia, 
alpha-adrenergic blockade and anticholinergic effects. 
It can therefore be concluded that these agents may be 
useful and, where psychosis or delirium with psychotic 
symptoms are present, a trial, at initial doses of not more 
than 1 mg of haloperidol, or the equivalent, is indicated; 
at higher doses, EPSE can be expected. It is also worth 
noting that an adequate trial of any anti-psychotic re-
quires at least a week of treatment at any dosage incre-
ment, if not longer.
Given the high risk of EPSE and TD, the newer, 
second-generation or ‘atypical’ antipsychotics may be a 
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reasonable first-line approach, and are clearly a rational 
second line when EPSE have become apparent. Theoreti-
cally, at least, an additional advantage of these agents 
is their high potency as serotonin 5HT2A receptor an-
tagonists, which may be a useful effect as pro-phylaxis 
against, and treatment of, progressive multifocal leuco-
encephalopathy.43 Risperidone was shown to be effec-
tive in the treatment of HIV-associated psychotic and 
manic symptoms in one series of 17 cases,44 where a 
particularly good response in patients with manic symp-
toms was noted. EPSE can however be a problem, even 
in low doses,45 and severe complications as a result of 
interactions with ritonavir have been described.46 There 
is very little literature of substance on the use of other 
second-generation agents, other than for short-term, 
symptomatic use in delirium. Some care must be taken 
with olanzapine, owing to metabolism by CYP2D6 (the 
same may be said of clozapine), but the low risk of EPSE 
and growing evidence of their efficacy as mood stabi-
lisers10 make these agents compelling choices. The use 
of clozapine may be considered in HIV-positive patients 
with treatment-resistant schizophrenia, but given this 
drug’s association with neutropenia it is best used as a 
last resort in settings where CD4 counts remain high and 
white cell counts can be closely monitored.
DeliriUM
As mentioned at the outset, the most critical step in 
managing delirium in the setting of HIV infection is to 
vigorously identify and treat possible causes (see the ar-
ticle on assessment and treatment of psychosis in HIV-
infected individuals in this issue). The short-term use of 
low-dose antipsychotics and/or benzodiazepines may be 
considered if clinically indicated to manage behavioural 
disturbance.
HiV-assOciaTeD DeMenTia
As described elsewhere in this issue, the mainstay of 
treatment of HIV-associated dementia is ART, but short-
term, symptomatic use of antipsychotics and mood sta-
bilisers may be helpful.
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